摘要
目的探讨拉米夫定联合舒血宁注射液治疗慢性乙肝的临床疗效。方法选择我院慢性乙肝患者83例,以上患者随机分为两组,观察组和对照组。对照片组给予拉米夫定治疗,疗程为48周。治疗组给予拉米夫定联合舒血宁注射液治疗。在治疗前、治疗后的第12、24、48周检查两组患者的肝功能、血清乙肝标志物和HBV-DNA定量。在治疗前以及治疗后第48周检测YMDD变异株。结果 1治疗组治疗后48周ALT复常率与对照组同期比较,差异有统计学意义,P<0.05。2治疗组患者在治疗后12、24、48周HbeAg转阴率和HbeAg/HbeAb血清转换与对照组同期比较,差异无统计学意义,P>0.05。3治疗组治疗48周后HBV-DNA转阴率与对照组同期比较,差异有统计学,P<0.05。4治疗组治疗48周后YMDD变异株发生率与对照组周期比较,差异有统计学,P<0.05。5两组患者治疗后总有效率比较,差异有统计学意义,P<0.05。结论舒血宁联合拉米夫定治疗慢性乙肝可以提高HBV-DNA阴转率,减少使用拉米夫定治疗后所导致乙肝病毒YMDD变异的发生,并促进肝功能恢复,疗效显著。
Objective To invesigate the therapeutic effection of shu xue ning injection combined with lamivudine to treat chronic hepatitis B. Methods 83 cases with chronic hepatitis B were selected, andrandomly divided into two groups, observation group and control group. The control group was treated with lamivudene alone, and the observation group was treated with lamivudine comblined with shuxuening infection, both groups received treatment for 48 weeks. The liver function、hepatitis Bmarkers of serum、HBV-DNA quantification were detectedbefore and the point of 12, 24, 48 weeks, after treating. Observing the condition of YMDD mutation at the beginning of treatment andthepontof 48weeks after treating. Results①After 48 weeks of treatment, the reeovery rates of ALT in the observation group compared with that of the same period in control group.ghere was statistical difference, P〈0.05.②The rates of BbeAg turning megative and the rates of HbeAh seroeonversion in the observation group after 12weeks,24weeks,47weeks compared with those of the same period,there was no statistical difference, P〉0.05.③The rates of HBV-DNA turning negative in observation group afer 48weeks compared with that of the same period in control group, there was statistical difference, P〈0.05.④After 48 weeks of treatment, the rates of YMDD mutation in the observation group compared with that of the same period in control group. There was statistical difference, P〈0.05.⑤After 48 weeks of treatment,the total rate of clinical efficacy in the observation group compared with that of the same period in control group. There was statistical differecne, P〈0.05. Conclusions Shuxuening incidence of YMDD mutation caused by application of lamivudeine, and improve the liver funciton, the therapy has significant clinical effection.
出处
《中国医药指南》
2014年第22期25-26,共2页
Guide of China Medicine
